There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
|Articles|August 24, 2006
Headline
Description
Advertisement
Article Body
Disclosures:
The author(s) have no significant financial interest or other relationship with the manufacturers of any products orproviders of any service mentioned in this article.
Advertisement
Related to this article
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Review top pipeline updates from last week.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
The New, Impending Adult ADHD Guidelines
4
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
5